Immuron Limited Sponsored ADR IMRN 深 滬
已收盤 02-06 16:00:00 美东时间
0.8058
+0.026
+3.31%
華盛通- 最 高0.84
- 今 開0.839
- 成交量 2.58万股
- 最 低 0.796
- 昨 收 0.78
- 總市值 651.33万
- 52周最高 2.39
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 0.6765
- 委 比 91.06%
- 總股本 808.30万
- 歷史最高 28.99
- 量 比 1.12
- 振 幅 5.64%
- 歷史最低 0.6765
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron Reports Continued Sales Growth
Immuron Limited reported H1 sales growth of Travelan® and ProIBS® across key markets. Global H1 sales reached AUD$4.2 million, up 5% YoY, with Australia leading at AUD$3.3 million (+13%) and the U.S. at AUD$0.9 million (+17%). Canada saw Q2 sales surge 191% after a slow start. ProIBS® launched in Australia ahead of schedule and will expand in Canada, targeting increased consumer awareness. The company attributes growth to marketing efforts, new s...
01-19 11:00
Immuron shares are trading lower after the topline results from a clinical trial of IMM‑124E failed to meet the primary endpoint.
Immuron shares are trading lower after the topline results from a clinical tria...
2025-12-11 03:43
Immuron Announces A New Research Agreement With The Naval Medical Research Command And The Walter Reed Army Institute Of Research, Funded By U.S. Department Of Defense Subaward
As previously announced on August 16, 2024, the Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting
2025-12-03 19:02
Immuron Secures U.S. Defense Award for Diarrheal Disease Therapeutics
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited has a...
2025-12-03 10:47
Immuron Limited Director Increases Stake with Shareholder Approval
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited annou...
2025-11-21 16:05
Immuron IMM-529 IND approved by FDA
Immuron receives FDA approval for its IMM-529 IND application, allowing a Phase 2 clinical trial for treating *Clostridioides difficile* infection (CDI). The trial will enroll up to 60 subjects in Australia, testing IMM-529 combined with standard of care (SOC) antibiotics. IMM-529 targets C. diff toxins and spores, showing potential in preventing and treating primary and recurrent CDI. If successful, it could generate up to $400M annually. CDI af...
2025-11-05 11:00
Immuron reports delay in Travelan study data
Immuron (IMRN) announced that the results from its Travelan P2TD study, conducted by the Uniformed Services University, will be postponed until the end of November because of the U.S. government shutd...
2025-10-31 21:36
Immuron Completes Minor Protocol Updates For IMM-529 IND Following FDA Request For Additional Clinical Information
IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to
2025-10-31 18:05
Immuron Announces Clinical Trial Update
Immuron Limited provided updates on its clinical trials for Travelan® and IMM-529. The IMM-529 IND application for preventing or treating Clostridioides difficile infection is currently under review by the FDA, with Immuron responding to the agency's requests. The Travelan® P2TD study at the Uniformed Services University, involving 851 participants, has been delayed until late November due to the U.S. government shutdown. The study's results will...
2025-10-31 10:00
Immuron Limited Launches PROIBS® for IBS Relief in Australia
Immuron Limited ( ($AU:IMC) ) has shared an update. Immuron Limited has launche...
2025-10-24 08:37
